Erratum: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424)

Research output: Contribution to journalComment/debatepeer-review

Abstract

The article by Krop et al entitled “Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I” (JCO Prec Oncol 10.1200/PO.21. 00424) was published online February 9, 2022, with an error.

Original languageEnglish (US)
Article numbere2200116
JournalJCO Precision Oncology
Volume6
DOIs
StatePublished - 2022
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Erratum: Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I (JCO Prec Oncol DOI: 10.1200/PO.21.00424)'. Together they form a unique fingerprint.

Cite this